All In Biotech

Drug Trial Radar · NCT05133180

Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)

A 4-week, Phase III, Multicenter, Double-masked, Vehicle-controlled Clinical Study to Evaluate Safety and Efficacy of Oxervate® (Cenegermin) 20 mcg/mL Ophthalmic Solution vs Vehicle in Severe Sjogren's Dry Eye Disease

Last checked: Nov 20, 2026Latest source record: Jun 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

104

Actual

Start

Jan 19, 2022

Primary completion

Sep 22, 2022

Study completion Dec 19, 2022

Sponsor

Lead sponsor
Dompé Farmaceutici S.p.AIndustry
Sponsor type
Industry
First posted
Nov 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objectives * To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) \>10mm/5min at Week 4 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in Symptom Assessment in Dry Eye questionnaire (SANDE) global score at Week 12 by testing the superiority. Secondary objectives * To compare the efficacy of cenegermin vs vehicle in Schirmer I test at Week 4, 8, 12 and 16 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in Cornea and conjunctiva vital staining with fluorescein (National Eye Institute \[NEI\] scales) at Week 4, 8, 12 and 16 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in Tear Film Break-Up Time (TFBUT) at Week 4, 8, 12 and 16 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in SANDE scores at Week 8, 12 and 16 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in worsening in symptom scores (SANDE) and/or NEI score at Week 4 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in impact of dry eye on everyday life (IDEEL) questionnaire at Week 4, 8, 12 and 16 by testing the superiority.

Conditions

  • Dry Eye

Interventions

  • OxervateDrug

    Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID).

  • VehicleOther

    Vehicle will be instilled with the same scheme of the test product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Reaching a Value of Schirmer I Test (Without Anaesthesia) >10mm/5min at Week 4Time frame: at week 4
  2. Change From Baseline in Symptoms Questionnaire (SANDE) Global Score at Week 12Time frame: at week 12

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Lugene Eye Institute - Glendale Office

    Glendale, California

  • David Wirta, M.D. & Associates

    Newport Beach, California

  • The Johns Hopkins University

    Baltimore, Maryland

  • Tufts University School of Medicine (TUSM) - New England Eye Center/Tufts Medical Center - Boston

    Boston, Massachusetts

  • Houston Eye Associates HEA - Gramercy Location

    Houston, Tennessee

  • Toyos Clinic - Nashville

    Nashville, Tennessee

  • Virginia Eye Consultants (VEC) - Norfolk Office

    Norfolk, Virginia

  • AOU Gaspare Rodolico - Ospedale San Marco

    Catania, Italy

  • Università degli Studi di Milano - Ospedale San Giuseppe - UO Oculistica

    Milan, Italy

  • AOU Policlinico Umberto I - Dipartimento Organi di Senso - Clinica Oculistica

    Roma, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.